Bone marrow mesenchymal stromal cells of patients with myeloproliferative disorders do not carry the JAK2-V617F mutation

Experimental Hematology

Volumn 37, Issue 3, 2009, Pages 416-420

  Mercier, François ^a   Monczak, Yury ^a   François, Moïra ^a   Prchal, Jaroslav ^b   Galipeau, Jacques ^a,b  

^a MCGILL UNIVERSITY   (Canada)

^b MCGILL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

DNA;

ADULT; AGED; ARTICLE; BONE MARROW CELL; CELL CLONE; CELL DIFFERENTIATION; CELL ISOLATION; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; FUSION GENE; GENE MUTATION; HEMATOPOIETIC STEM CELL; HUMAN; HUMAN CELL; JAK2 V617F GENE; MALE; MESENCHYME CELL; MYELOPROLIFERATIVE DISORDER; PHENOTYPE; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION;

BONE MARROW CELLS; CELL LINEAGE; HUMANS; JANUS KINASE 2; MESENCHYMAL STEM CELLS; MUTATION, MISSENSE; MYELOPROLIFERATIVE DISORDERS; POLYMERASE CHAIN REACTION; TUMOR CELLS, CULTURED;

EID: 59749086848     PISSN: 0301472X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.exphem.2008.11.008     Document Type: Article

References (24)

1. Baxter E.J., Scott L.M., Campbell P.J., et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 365 (2005) 1054-1061
2. Levine R.L., Wadleigh M., Cools J., et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell 7 (2005) 387-397
3. James C., Ugo V., Le Couedic J.-P., et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature 434 (2005) 1144-1148
4. Kralovics R., Passamonti F., Buser A.S., et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med 352 (2005) 1779-1790
5. Delhommeau F., Dupont S., Tonetti C., et al. Evidence that the JAK2 G1849T (V617F) mutation occurs in a lymphomyeloid progenitor in polycythemia vera and idiopathic myelofibrosis. Blood 109 (2007) 71-77
6. Pardanani A., Lasho T.L., Finke C., et al. Extending Jak2V617F and MplW515 mutation analysis to single hematopoietic colonies and B and T lymphocytes. Stem Cells 25 (2007) 2358-2362
7. Zwezdaryk K.J., Coffelt S.B., Figueroa Y.G., et al. Erythropoietin, a hypoxia-regulated factor, elicits a pro-angiogenic program in human mesenchymal stem cells. Exp Hematol 35 (2007) 640-652
8. Van Slyck E.J., Weiss L., and Dully M. Chromosomal evidence for the secondary role of fibroblastic proliferation in acute myelofibrosis. Blood 36 (1970) 729-735
9. Jacobson R.J., Salo A., and Fialkow P.J. Agnogenic myeloid metaplasia: a clonal proliferation of hematopoietic stem cells with secondary myelofibrosis. Blood 51 (1978) 189-194
10. Singer J.W., Keating A., Cuttner J., et al. Evidence for a stem cell common to hematopoiesis and its in vitro microenvironment: studies of patients with clonal hematopoietic neoplasia. Leuk Res 8 (1984) 535-545
11. Eliopoulos N., Stagg J., Lejeune L., Pommey S., and Galipeau J. Allogeneic marrow stromal cells are immune rejected by MHC class I- and class II-mismatched recipient mice. Blood 106 (2005) 4057-4065
12. Takashima Y., Era T., Nakao K., et al. Neuroepithelial cells supply an initial transient wave of MSC differentiation. Cell 129 (2007) 1377-1388
13. Ogawa M., LaRue A.C., and Drake C.J. Hematopoietic origin of fibroblasts/myofibroblasts: Its pathophysiologic implications. Blood 108 (2006) 2893-2896
14. Keating A., Singer J.W., Killen P.D., et al. Donor origin of the in vitro haematopoietic microenvironment after marrow transplantation in man. Nature 298 (1982) 280-283
15. Tanaka J., Kasai M., Imamura M., et al. Evaluation of mixed chimaerism and origin of bone marrow derived fibroblastoid cells after allogeneic bone marrow transplantation. Br J Haematol 86 (1994) 436-438
16. Flores-Figueroa E., Arana-Trejo R.M., Gutierrez-Espindola G., Perez-Cabrera A., and Mayani H. Mesenchymal stem cells in myelodysplastic syndromes: phenotypic and cytogenetic characterization. Leuk Res 29 (2005) 215-224
17. Copland I., Jolicoeur E., Gillis M., et al. Coupling erythropoietin secretion to mesenchymal stromal cells enchances their regenerative properties. Cardiovasc Res 79 (2008) 405-415
18. DiGirolamo C., Stokes D., Colter D., Phinney D.G., Class R., and Prockop D. Propagation and senescence of human marrow stromal cells in culture: a single colony-forming assay identifies samples with the greatest potential to propagate and differentiate. Br J Haematol 107 (2001) 275-281
19. Bonab M., Alimoghaddam K., Talebian F., Ghaffari S., Ghavamzadeh A., and Nikbin B. Aging of mesenchymal stem cell in vitro. BMC Cell Biol 7 (2006) 14
20. Phinney D.G., Kopen G., Righter W., Webster S., Tremain N., and Prockop D.J. Donor variation in the growth properties and osteogenic potential of human marrow stromal cells. J Cell Biochem 75 (1999) 424-436
21. Jones A.V., Silver R.T., Waghorn K., et al. Minimal molecular response in polycythemia vera patients treated with imatinib or interferon alpha. Blood 107 (2006) 3339-3341
22. Tefferi A. Pathogenesis of myelofibrosis with myeloid metaplasia. J Clin Oncol 23 (2005) 8520-8530
23. Jamieson C.H.M., Gotlib J., Durocher J.A., et al. The JAK2 V617F mutation occurs in hematopoietic stem cells in polycythemia vera and predisposes toward erythroid differentiation. Proc Natl Acad Sci U S A 103 (2006) 6224-6229
24. Wohrer S., Rabitsch W., Shehata M., et al. Mesenchymal stem cells in patients with chronic myelogenous leukaemia or bi-phenotypic Ph+ acute leukaemia are not related to the leukaemic clone. Anticancer Res 27 (2007) 3837-3841